Imaging and blood test study for men with advanced prostate cancer on PARP drugs
Part of Cancer, Kidney & urinary clinical trials.
This study uses a special PET scan (FTT-PET) and a blood test (ctDNA) to see if they can predict how well PARP inhibitor therapy works in men with metastatic prostate cancer that has specific genetic mutations. It aims to improve treatment decisions by identifying which patients benefit most from these drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have metastatic prostate cancer that is resistant to hormone therapy (castration-resistant) and has a specific genetic change (like BRCA or ATM).
- You are scheduled to start treatment with a PARP inhibitor (a type of targeted drug) as part of your standard care.
- You have at least one tumor that is 1 cm or larger on a scan, or a clearly visible lesion on another imaging test like a bone scan or PSMA-PET.
- You are on continuous hormone therapy (ADT) and your testosterone level is very low (below 50 ng/dL), or you have had your testicles removed.
- Your PSA level is 2 ng/mL or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This research study examines circulating tumor cells (cancer cells in the bloodstream) to better understand which patients might benefit from PARP inhibitor drugs. You'll have blood samples collected to help doctors personalize cancer treatment decisions.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.